Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Shilpa Medicare Limited ( (IN:SHILPAMED) ) is now available.
Shilpa Medicare Limited, through its wholly owned subsidiary Koanna International FZ LLC, has entered into a joint venture with Pharma Pharmaceutical Industries & Biological Products (PPI) to establish a new pharmaceutical manufacturing facility in Saudi Arabia. This strategic move is expected to enhance Shilpa’s global footprint and strengthen its presence in the MENA region, allowing the company to supply and locally manufacture pharmaceutical formulations, thereby consolidating its market position.
More about Shilpa Medicare Limited
Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is known for its expertise in producing a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). It aims to expand its market presence, particularly in the MENA region.
Average Trading Volume: 8,724
Technical Sentiment Signal: Buy
Current Market Cap: 80.53B INR
For a thorough assessment of SHILPAMED stock, go to TipRanks’ Stock Analysis page.